Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q1 2024 · 10-Q
Revenue$202.20M$202.20M+11.6% vs Q1 2023 Net Income-$26.00M-$26.00MN/M vs Q1 2023 EPS Diluted-$0.29-$0.29N/M vs Q1 2023 Gross Profit$137,600,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flow-$18,600,000N/M Margins · derivedGross margin68.1%
Operating margin-13.8%+15.0 pt vs Q1 2023
Net margin-12.9%+17.3 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end